Reneo Pharmaceuticals Inc RPHM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.65
- Day Range
- $1.66–1.71
- 52-Week Range
- $0.98–10.98
- Bid/Ask
- $1.67 / $1.80
- Market Cap
- $55.81 Mil
- Volume/Avg
- 115,223 / 177,471
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.reneopharma.com
Comparables
Valuation
Metric
|
RPHM
|
IMVT
|
PNT
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 11.36 |
Price/Book Value | 0.63 | 5.93 | 3.12 |
Price/Sales | — | — | 5.50 |
Price/Cash Flow | — | — | 13.90 |
Price/Earnings
RPHM
IMVT
PNT
Financial Strength
Metric
|
RPHM
|
IMVT
|
PNT
|
---|---|---|---|
Quick Ratio | 5.66 | 21.56 | 9.01 |
Current Ratio | 5.87 | 22.14 | 9.14 |
Interest Coverage | — | — | — |
Quick Ratio
RPHM
IMVT
PNT
Profitability
Metric
|
RPHM
|
IMVT
|
PNT
|
---|---|---|---|
Return on Assets (Normalized) | −60.40% | −43.33% | 20.67% |
Return on Equity (Normalized) | −68.46% | −47.83% | 23.56% |
Return on Invested Capital (Normalized) | −67.67% | −52.69% | 23.38% |
Return on Assets
RPHM
IMVT
PNT
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jnysrlytny | Hwqj | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zpyxdrmz | Hklxpj | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ymshhfmh | Pxmmhmh | $97.8 Bil | |
MRNA
| Moderna Inc | Bsjmdfcbr | Gdrh | $41.3 Bil | |
ARGX
| argenx SE ADR | Rtrcldk | Ydhn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Cvtghdbdc | Nhqtt | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nbgxnvtz | Dnlhjwr | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hhkzznqc | Cbjkl | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dpfphccyt | Lsnbcb | $12.5 Bil | |
INCY
| Incyte Corp | Fgmypzzx | Pwvrfx | $11.6 Bil |